Indianapolis-based Exelead Inc. says it has delivered the first batch of the Pfizer-BioNTech COVID-19 vaccine manufactured at its Indy facility. The contract development company says through an agreement with Pfizer Inc. (NYSE: PFE), it plans to add up to 50 jobs.
Exelead says it recently expanded its facilities and is dedicated a portion of its manufacturing capacity to support the production of the vaccine.
“We are extremely proud to be part of the manufacture of the Pfizer-BioNTech COVID-19 Vaccine, knowing our work has the potential to help millions of people,” said John Rigg, chief executive officer of Exelead. “As a leader in complex drug manufacturing, Exelead is committed to leveraging our manufacturing capabilities and years of experience to help support the supply of the Pfizer-BioNTech COVID-19 Vaccine and increase the number of doses available.”
Kevin Nepveux, vice president of global supply for Pfizer, says agreements with companies such as Exelead is one of several ways the company has been able to ramp up manufacturing to produce more doses of the vaccine.